Overall Survival
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Shai Shimony, H Moses Murdock, Julia Keating, Harrison K Tsai, Archana Sasi, Christopher J Gibson, Stefan Faderl, Anthony Wagner, Nalina Dronamraju, Tara L Lin, Thomas Prebet, Jorge E Cortes, Geoffrey L Uy, Jeffrey E Lancet, Christopher R Reilly, Donna Neuberg, Richard M Stone, R Coleman Lindsley
Blood Adv 10(8) 2854-2864
CPX-351 was approved for the treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over standard cytarabine plus anthracycline (7+3) therapy is confined to molecularly defined AML subgroups by performing DNA sequencing in 184 patients enrolled in the pivotal phase 3 randomized trial. Patients were categorized hierarchically based on gene mutations: (1) TP53-AML, (2) DDX41-AML, (3) myelodysplasia-related AML (AML-MR) defined by the World Health Organization fifth edition criteria, or (4) other-AML. TP53-AML was subclassified as single (TP53single) or multihit (TP53multi) based on the number of alleles altered via mutation, deletion, or copy neutral loss of heterozygosity. Two-year OS differed significantly across molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), and DDX41-AML (70%) (P< .001). CPX-351 improved survival in patients with AML-MR compared with 7+3 (median, 9.7 vs 6.8 months; P = .037), with no benefit in TP53-AML or other-AML. For patients undergoing transplantation, CPX-351 improved 2-year survival (76% vs 27%; P< .01), an effect primarily observed in AML-MR. Multivariable analysis confirmed the independent association with survival of both CPX-351 and hematopoietic cell transplantation in AML-MR. TP53multi demonstrated significantly worse survival than TP53single (median, 3.8 vs 7.0 months; P = .004). The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, in which the primary prognostic factor was allelic state. This trial was registered at www.clinicaltrials.gov as #NCT01696084.
4 个 Figure · 8 个 KM 面板
Figure 1. Genetic reclassification and association with survival. (A) Comutation plot of mutations present at AML diagnosis in the 184 patients with available samples enrolled in the CLTR0310-301 study per the 3 clinical classifications. Each column represents an individual patient, with the rows representing genes or cytogenetic abnormalities and the colored bars representing mutations. The percentage at the end of each row represents the percentage of patients in each clinical group harboring a mutation in that gene. The colored bars represent the hierarchical genetic classification as follows: TP53 (green), DDX41 (yellow), AML-MR (blue), and other mutations (red). (B) OS by clinical classification among sequenced patients. (C) OS by genetic classification. Abn, abnormality; MRC-cyto, MRC by cytogenetics; MRC-secondary, MRC by prior MDS or CMML; ITD, internal tandem duplication; TKD, tyrosine kinase domain.
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel C
Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. OS by genetic classification and treatment arm (CPX-351 vs 7+3). (A) OS in AML-MR by treatment. (B) OS in TP53 -AML by treatment arm. (C) OS in other-AML by treatment arm. (D) OS in DDX41 -AML by treatment arm. Time is measured from random assignment.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Transplantation and clinical outcomes in AML-MR. (A) Simon-Makuch plot for OS in patients with AML-MR in which allogeneic HCT is considered as a time-dependent covariate. (B) Multivariable OS Cox regression analysis of patients with AML-MR. HCT is measured as a time-varying covariate.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. TP53 allelic status and outcome. (A) Lollipop plot of pathogenic TP53 mutations among patients enrolled in the CLTR0310-301 study irrespective of treatment arm allocation. Each lollipop corresponds to a mutation, with the height of the lollipop being proportional to the frequency of that mutation in the cohort. Missense mutations are depicted above the bar, whereas truncating variants are depicted below. (B) Ridge/rain plot depicting the distribution of TP53 variant allele fractions according to allelic status. (C) Comutation plot of TP53 -mutated patients according to allelic status. Each column represents a patient and each row represents a gene mutation or genetic abnormality, with the colored bars indicating the presence of that genetic abnormality. (D) OS in the overall cohort by TP53 mutation and allelic status. Del, deletion; TAD, transactivation domain.
Figure 4 · Panel D
Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。